🇺🇸 FDA
Patent

US 11207342

High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof

granted A61KA61K31/713A61P

Quick answer

US patent 11207342 (High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/713, A61P, A61P3/06